Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × infigratinib × Clear all

Phase

Phase 2 5 Phase 1 3 Phase 3 2 Phase 1/2 1

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Central Nervous System Neoplasms 1

Interventions

pembrolizumab 212 Carboplatin 118 Nivolumab 106 Gemcitabine 106 Paclitaxel 103 Cisplatin 86 Bevacizumab 84 Cyclophosphamide 77 Dexamethasone 66 Docetaxel 61 Injections 60 Pemetrexed 58 Capecitabine 55 atezolizumab 53 Rituximab 53 Fluorouracil 52 130-nm albumin-bound paclitaxel 52 Cetuximab 51 Oxaliplatin 46 Leucovorin 42 Lenalidomide 41 Ipilimumab 39 venetoclax 37 Azacitidine 35 Prednisone 33 fludarabine 32 Trastuzumab 32 Fulvestrant 32 Albumin-Bound Paclitaxel 32 Irinotecan 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05222165 2023-02-23

NEWEL

Helsinn Healthcare SA

Phase 1/2 Withdrawn

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡